Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy alone for Patients With Lung Cancer (POSEIDON).

Trial Identifier: D419MC00004
Sponsor: AstraZeneca
Start Date: June 2017
Primary Completion Date: March 2021
Study Completion Date: November 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version - Summary for Global Cohort
Afrikaans Translation
Bulgarian Translation
Hungarian Translation
Korean Translation
North Sotho Translation
Portuguese (Brazil) Translation
Russian Translation
Russian (Ukraine) Translation
Ukrainian Translation
Vietnamese Translation
Zulu Translation
German Translation
English (UK) Translation
Spanish (Mexico) Translation
Spanish (Peru) Translation
Japanese Translation
Polish Translation
Thai Translation
Chinese (China) Translation
Chinese (Hong Kong) Translation
Chinese (Taiwan) Translation

Trial Locations